Biomarker Unit of PPD Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Biomarker Unit of PPD Inc. - overview
Location
Wilmington, NC, US
Primary Industry
Business Support Services
About
Biomarker Unit of PPD Inc. is a global Contract Research Organization (CRO) that provides comprehensive drug development solutions, specializing in clinical trials and laboratory services across various therapeutic areas. Biomarker Unit of PPD Inc. operates as part of PPD, Inc.
, a prominent player in the pharmaceutical research sector. The company is headquartered in Wilmington, US. The firm was involved in a significant deal on January 22, 2010, when Caprion Proteomics, a portfolio company of Great Point Partners, acquired PPD Inc. No information on prior founders or subsidiary structures was disclosed.
PPD specializes in comprehensive solutions across the drug development continuum, offering Accelerator™ Drug Development services, clinical development, laboratory services, and functional service partnerships. These services cater to clients in over 20 therapeutic areas, addressing needs from established drug markets to innovative research. PPD's clientele includes biopharmaceutical companies and government entities, supporting clinical trials, vaccine development, and regulatory submissions, with a strong market presence in North America, Europe, and Asia-Pacific. PPD generates revenue predominantly through B2B transactions with biopharmaceutical clients, often secured via multi-year contracts or project-based engagements.
Revenue streams are diversified across laboratory services, clinical trial management, and pharmacovigilance solutions, with pricing structures tailored to project complexity. The company's Accelerator™ platform significantly contributes to its revenue framework by expediting drug development processes. PPD aims to enhance its portfolio with new products, although specific details on upcoming launches are not disclosed. The company is seeking to expand its operations into new geographic regions, targeting markets such as Asia and Europe by 2025.
The 2010 acquisition will likely support these growth initiatives, although exact financial details have not been specified.
Current Investors
Caprion Biosciences Inc.
Primary Industry
Business Support Services
Sub Industries
Business Support Services, Healthcare
Website
www.ppdi.com
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Biomarker Unit of PPD Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Biomarker Unit of PPD Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.